American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws

Journal of Oral and Maxillofacial Surgery

Volumn 65, Issue 3, 2007, Pages 369-376

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORHEXIDINE; CLINDAMYCIN; CORTICOSTEROID; DOXYCYCLINE; ERYTHROMYCIN; METRONIDAZOLE; PAMIDRONIC ACID; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ANTIBIOTIC THERAPY; ARTICLE; BONE METASTASIS; BONE NECROSIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEBRIDEMENT; DENTAL CARE; DISEASE CLASSIFICATION; DRUG WITHDRAWAL; HEALTH CARE ORGANIZATION; HUMAN; HYPERBARIC OXYGEN; HYPERCALCEMIA; INCIDENCE; JAW DISEASE; MOUTH HYGIENE; MOUTH INFECTION; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE; RISK ASSESSMENT; RISK FACTOR;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; CONSENSUS; DIPHOSPHONATES; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; JAW DISEASES; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, DENTAL; UNITED STATES;

EID: 33847284113     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2006.11.003     Document Type: Article

References (54)

1. Nussbaum S.R., Younger J., Vandepol C.J., et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 95 (1993) 297
2. Major P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled, clinical trials. J Clin Oncol 19 (2001) 558
3. Hortobagyi G.N., Theriault R.L., Porter L., et al., Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335 (1996) 1785
4. Hortobagyi G.N., Theriault R.L., Lipton A., et al., Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16 (1998) 2038
5. Hillner B.E., Ingle J.N., Chelbowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042
6. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458
7. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879
8. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind placebo-controlled trial. Cancer 100 (2004) 2613
9. Berenson J.R., Lichtenstein A., Porter L., et al., Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 (1996) 488
10. Berenson J.R., Lichtenstein A., Porter L., et al., Myeloma Aredia Study Group. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16 (1998) 593
11. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III double-blind, comparative trial. Cancer J 7 (2002) 377
12. Berenson J.R., Hillner B.E., Kyle R.A., et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719
13. Physicians' Desk Reference. (ed 57) (2003), Medical Economics, Montvale, NJ
14. Delmas P.D., and Meunier P.J. The management of Paget's disease of bone. N Engl J Med 336 (1997) 558
15. Letocha A.D., Cintas H.L., Troendle J.F., et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20 (2005) 977
16. Watts N.B. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 19 (2003) 395
17. Delmas P.D. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 17 (2005) 462
18. Haderslev K.V., Tjellesen L., Sorensen H.A., et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 119 (2000) 639
19. Zein C.O., Jorgensen R.A., Clarke B., et al. Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. Hepatology 42 (2005) 762
20. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189
21. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
22. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
23. Estilo C.L., Van Posnak C.H., Williams T., et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study. J Clin Oncol Proc Am Soc Clin Oncol 22 (2004) 8088
24. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 63 (2005) 1567
25. Migliorati C.A., Schubert M.M., Peterson D.E., et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83
26. Purcell P.M., and Boyd I.W. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 182 (2005) 417
27. Bagan J.V., Jimenez Y., Murillo J., et al. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 42 (2006) 327
28. Pires F.R., Miranda A., Cardoso E.S., et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 11 (2005) 365
29. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753
30. Woo S.B., Hande K., and Richardson P.G. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med 353 (2005) 100
31. Hohnecker JA: Novartis "Dear Doctor" precautions added to label of Aredia and Zometa. September 24, 2004
32. US Food and Drug Administration Oncologic Drugs Advisory Committee: Combidex briefing information. http://www.fda.gov/ohms/dockets/ac/05/briefing/2005-4095B2_02_08-Novartis-Zometa-App-7.pdf. Accessed August 14, 2006
33. U.S. Food and Drug Administration Office of Drug Safety: Postmarketing Safety Review. Available at: www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_03_04-FDA-TAB3.pdf - 03-02-2005. Accessed August 14, 2006
34. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med 353 (2005) 99
35. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (2005) 8580
36. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica (2006) 91 [Epub ahead of print]
37. Dimopoulos M., Kastritis E., Moulopoulos L.A., et al. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate. Blood (American Society of Hematology Annual Meeting Abstracts) 106 (2005) 637
38. Tosi P., Zamagni E., Cangini D., et al. Bisphosphonates and osteonecrosis of the jaws: Incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. Blood (American Society of Hematology Annual Meeting Abstracts) 106 (2005) 3461
39. Pozzi S., Marcheselli R., Sacchi S., et al. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. Blood (American Society of Hematology Annual Meeting Abstracts) 106 (2005) 5057
40. Cafro A.M., Barbarano L.A., Andriani A., et al. Osteonecrosis of the jaw associated with chroninc bisphosphonates therapy: An Italian experience. Blood (American Society of Hematology Annual Meeting Abstracts) 106 (2005) 5152
41. Zavras A.I., and Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis?. J Oral Maxillofac Surg 64 (2006) 917
42. Hoff AO, Toth BB, Altundag K, et al: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006 ASCO Annual Meeting Proceedings (post meeting edition). 24:8528, 2006. Available at: http://meeting.jco.org/cgi/content/abstract/24/18_suppl/8528. Accessed August 14, 2006
43. IMS HEALTH, NPA Plus May 2006
44. Report of the Council of Scientific Affairs. Expert panel recommendations: Dental management of patients on oral bisphosphonate therapy. American Dental Association. June 2006. Available at: http://www.ada.org/prof/resources/topics/osteonecrosis.asp. Accessed June 29, 2006
45. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24 (2006) 945
46. Ruggiero S.L., Fantasia J., and Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Path Oral Radiol Endod 102 (2006) 433
47. Ruggiero S.L., Gralow J., Marx R.E., et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Clin Oncol Prac 2 (2006) 7
48. Migliorati C.A., Casiglia J., Epstein J., et al. Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc 136 (2005) 1658
49. American Association of Endodontists: Position Statement: Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws. Available at: http://www.aae.org/dentalpro/guidelines.htm. Accessed August 14, 2006
50. Novartis Media Release. New data demonstrate benefits of once-yearly Aclasta in the treatment of postmenopausal osteoporosis. September 16, 2006. Available at: http://cws.huginonline.com/N/134323/PR/200609/1075407_5.html. Accessed September 22, 2006
51. Kademani D., Koka S., Lacy M.Q., et al. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81 (2006) 1100
52. Chhoeu A.H., Siegel D., Landesberg R., et al. A case series of hyperbaric oxygen treatment for non-radiation induced osteonecrosis of the jaw. J Oral Maxillofac Surg 64 suppl (2006) 80
53. National Institutes of Health Program Announcement. Available at: http://grants2.nih.gov/grants/guide/pa-files/PA-06-500.html. Accessed September 15, 2006
54. National Institutes of Health Computer Retrieval of Information on Scientific Projects. Available at: http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=7145967&p_grant_num=1R21DE017164-01A1&p_query=(osteonecrosis)&ticket=24536900&p_audit_session_id=133450496&p_audit_score=33&p_audit_numfound=2&p_keywords=osteonecrosis. Accessed September 14, 2006